iNtRON Biotechnology, Inc.

KOSDAQ 048530.KQ

iNtRON Biotechnology, Inc. Capital Expenditure for the year ending December 31, 2023: USD -7.09 M

iNtRON Biotechnology, Inc. Capital Expenditure is USD -7.09 M for the year ending December 31, 2023, a -242.97% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

iNtRON Biotechnology, Inc. Capital Expenditure for the year ending December 31, 2022 was USD -2.07 M, a 29.32% change year over year.
iNtRON Biotechnology, Inc. Capital Expenditure for the year ending December 31, 2021 was USD -2.92 M, a 47.51% change year over year.
iNtRON Biotechnology, Inc. Capital Expenditure for the year ending December 31, 2020 was USD -5.57 M, a -860.75% change year over year.
iNtRON Biotechnology, Inc. Capital Expenditure for the year ending December 31, 2019 was USD -580.03 K, a 11.53% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

KOSDAQ: 048530.KQ

iNtRON Biotechnology, Inc.

CEO	Mr. Seong-Jun Yoon
IPO Date	Jan. 26, 2011
Location	South Korea
Headquarters	137, Sagimakgol-ro
Employees	76
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Vaccines

Description

iNtRON Biotechnology, Inc. develops biopharmaceuticals for the prevention and treatment of human diseases worldwide. It develops bacteriophage and endoricin drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.

Key trends

Past 5 years